Advertisement

Determination of lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone in human plasma for CYP2C19 and CYP3A4 phenotyping

  • Katarína Kostolanská
  • Ondřej Peš
  • Ondřej Zendulka
  • Jan Máchal
  • Jan JuřicaEmail author
Original Paper
  • 51 Downloads

Abstract

A simple and sensitive liquid chromatography method with absorbance or mass spectrometry detection was developed and validated for the determination of lansoprazole, lansoprazole sulfone, and 5-hydroxylansorpazole in human serum with omeprazole as an internal standard. Analytes were, after an extraction step with a mixture of isopropyl alcohol: dichloromethane (2:8, v/v), separated in a gradient elution (acetonitrile: 20 mM ammonium formate) and detected at 280 and 300 nm or by monitoring selective reactions in a triple quadrupole mass analyzer. The limits of detection were, for all analytes, below 2 ng/mL and 3 pg/mL in the LC UV and LC MS method, respectively. The combined linear dynamic range exceeded 5 orders of magnitude. The method was successfully applied in the assessment of CYP2C19 and CYP3A4 metabolic phenotypes in ST-elevated myocardial infarction patients receiving novel anticoagulant treatment.

Keywords

Cytochrome P450 Phenotype Lansoprazole 5-Hydroxylansoprazole Lansoprazole sulfone Liquid chromatography Mass spectrometry Metabolites 

Notes

Acknowledgements

This work was supported by funds from the Faculty of Medicine MU to a junior researcher Ondřej Peš and by the Specific University Research Grant (MUNI/A/1132/2017, MUNI/A/0910/2017) provided by the Ministry of Education, Youth and Sports of the Czech Republic and by the project no. LQ1605 from the National Program of Sustainability II (MEYS CR).

Compliance with ethical standards

Conflict of interest

Authors declare there are no potential conflicts of interest to disclose.

References

  1. Aoki I, Okumura M, Yashiki T (1991) High-performance liquid-chromatographic determination of lansoprazole and its metabolites in human serum and urine. J Chromatogr Biomed Appl 571:283–290CrossRefGoogle Scholar
  2. Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, Simonsson USH, Ashton M (2007) Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 21:307–316CrossRefGoogle Scholar
  3. Belal F, El-Enany N, Rizk M (2004) Anodic polarographic determination of lansoprazole and omeprazole in pure form and in pharmaceutical dosage forms. J Food Drug Anal 12:102–109Google Scholar
  4. Bharathi DV, Hotha KK, Jagadeesh B, Chatki PK, Thriveni K, Mullangi R, Naidu A (2009) Simultaneous estimation of four proton pump inhibitors–lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. Biomed Chromatogr 23:732–739CrossRefGoogle Scholar
  5. Chung H, Truong Q, Mai X, Choi Y, Kang J, Mar W, Kim K (2017) Determination of S-(-)-lansoprazole in dexlansoprazole preparation by capillary zone electrophoresis. Arch Pharm Res 40:962–971CrossRefGoogle Scholar
  6. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang HL, Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450 s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23–29Google Scholar
  7. Dogrukol-Ak D, Tuncel M, Aboul-Enein H (2001) The determination of lansoprazole in pharmaceutical preparation by capillary electrophoresis. Chromatographia 54:527–530CrossRefGoogle Scholar
  8. Dynamed American Society of Health System Pharmacists, I, 1995–2018 (2018) Dynamed. EBSCO Information Services, IpswichGoogle Scholar
  9. Elkady EF, Fouad MA, Jaadan BM (2018) LC-MS/MS bioassay of four proton pump inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci 1076:61–69CrossRefGoogle Scholar
  10. FDA (2018) Bioanalytical method validation, guidance for industry. In: U.S. Department of Health and Human Services, F. A. D. A., Center for Drug Evaluation and Research (CDER) (Ed.). FDA, p 44Google Scholar
  11. Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109–116CrossRefGoogle Scholar
  12. Ganesh M, BhagiyaLakshmi M, Hemalatha P, Patil R, Sakthimanigandan K, Jang HT, Rajasekar K (2011) Liquid chromatography-electrospray tandem mass spectrometry (LC-MS/MS) determination of lansoprazole in human plasma. J Liq Chromatogr Relat Technol 34:129–142CrossRefGoogle Scholar
  13. Gumus E, Karaca O, Babaoglu M, Baysoy G, Balamtekin N, Demir H, Uslu N, Bozkurt A, Yuce A, Yasar U (2012) Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 68:629–636CrossRefGoogle Scholar
  14. Jackson PR, Tucker GT, Woods HF (1989) Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism–histograms and probit plots. Br J Clin Pharmacol 28:647–653CrossRefGoogle Scholar
  15. Kim K, Kim M, Park J, Shon J, Yoon Y, Lee S, Liu K, Chun J, Hyun M, Shin J (2003) Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31:1227–1234CrossRefGoogle Scholar
  16. Landes B, Miscoria G, Flouvat B (1992) Determination of lansoprazole and its metabolites in plasma by high-performance liquid-chromatography using a loop column. J Chromatogr Biomed Appl 577:117–122CrossRefGoogle Scholar
  17. Luo L, Wen X, Du Y, Jiang Z, Guo X (2018) Enantioselective analysis of lansoprazole in rat plasma by LC–MS/MS: application to a stereoselective pharmacokinetic study. Biomed Chromatogr 32:4345CrossRefGoogle Scholar
  18. Medicines and Healthcare Regulatory Agency (MHRA) (2017) SmPC, Zoton FasTab. In: MHRA (ed), pp 1–14Google Scholar
  19. Nassar MY, El-Shahat MF, Khalil SM, El-Moety EA (2017) Optimization and validation of spectrophotometric and potentiometric methods for determination of lansoprazole and omeprazole in pure and capsules. Indian J Pharm Sci 79:420–430CrossRefGoogle Scholar
  20. Oliveira CH, Barrientos-Astigarraga RE, Abib E, Mendes GD, da Silva DR, de Nucci G (2003) Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 783:453–459CrossRefGoogle Scholar
  21. Sharma A, Pilote S, Belanger PM, Arsenault M, Hamelin BA (2004) A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study. Br J Clin Pharmacol 58:288–297CrossRefGoogle Scholar
  22. Sohn D, Kwon J, Kim H, Ishizaki T (1997) Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 61:574–582CrossRefGoogle Scholar
  23. Song M, Gao X, Hang T, Wen A (2008) Simultaneous determination of lansoprazole and its metabolites 5′-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal 48:1181–1186CrossRefGoogle Scholar
  24. Song M, Gao X, Hang TJ, Wen AD (2009) Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: a single-dose, open-label study in healthy Chinese male subjects. Curr Ther Res Clin Exp 70:228–239CrossRefGoogle Scholar
  25. Sun L, Cao Y, Jiao H, Fang Y, Yang Z, Bian M, Zhang H, Gong X, Wang Y (2015) Enantioselective determination of (R)- and (S)-lansoprazole in human plasma by chiral liquid chromatography with mass spectrometry and its application to a stereoselective pharmacokinetic study. J Sep Sci 38:3696–3703CrossRefGoogle Scholar
  26. Swar BD, Bendkhale SR, Rupawala A, Sridharan K, Gogtay NJ, Thatte UM, Kshirsagar NA (2016) Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping. Indian J Pharmacol 48:248–251CrossRefGoogle Scholar
  27. Turjap M, Zendulka O, Glatz Z, Brejcha S, Madr A, Jurica J (2016) Determination of caffeine and its metabolites in saliva and urine as a measure of CYP1A2 metabolic activity. Curr Pharm Anal 12:325–332CrossRefGoogle Scholar
  28. Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T (2005a) Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Anal Technol Biomed Life Sci 816:309–314CrossRefGoogle Scholar
  29. Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T (2005b) Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci 816:309–314CrossRefGoogle Scholar
  30. Wang H, Sun Y, Meng X, Yang B, Wang J, Yang Y, Gu J (2015) Determination of lansoprazole enantiomers in dog plasma by column-switching liquid chromatography with tandem mass spectrometry and its application to a preclinical pharmacokinetic study. J Sep Sci 38:2960–2967CrossRefGoogle Scholar
  31. Wu GL, Zhou HL, Shentu JZ, He QJ, Yang B (2008) Determination of lansoprazole in human plasma by rapid resolution liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. J Pharm Biomed Anal 48:1485–1489CrossRefGoogle Scholar
  32. Xu HR, Chen WL, Li XN, Chu NN (2010) The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol 48:947–952CrossRefGoogle Scholar
  33. Yanagida Y, Watanabe M, Takeba Y, Kumai T, Matsumoto N, Hayashi M, Suzuki S, Kinoshita Y, Kobayashi S (2009) Potential of lansoprazole as a novel probe for cytochrome P450 3A activity by measuring lansoprazole sulfone in human liver microsomes. Biol Pharm Bull 32:1422–1426CrossRefGoogle Scholar
  34. Yang DZ, Gao YY, Jiang XL, Dong WF, Tang DQ (2011) Pharmacokinetics of Lansoprazole Injection in Peptic Ulcer and Healthy Volunteers. Lat Am J Pharm 30:1016–1020Google Scholar
  35. Yeniceli D, Dogrukol-Ak D, Tuncel M (2004) Determination of lansoprazole in pharmaceutical capsules by flow injection analysis using UV-detection. J Pharm Biomed Anal 36:145–148CrossRefGoogle Scholar
  36. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37CrossRefGoogle Scholar
  37. Zhang D, Wang XL, Yang M, Wang GC, Liu HC (2011) Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica 41:511–517CrossRefGoogle Scholar
  38. Zhang H, Xia CH, Huang SB, Liu MY, Xiong YQ (2014) Determination of Lansoprazole in Human Plasma Using LC-MS and Pharmacokinetic Study in Chinese Healthy Volunteers. Lat Am J Pharm 33:624–630Google Scholar

Copyright information

© Institute of Chemistry, Slovak Academy of Sciences 2019

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  2. 2.Department of Pharmacology, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  3. 3.Department of Pathological Physiology, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  4. 4.Department of Human Pharmacology and ToxicologyUniversity of Veterinary and Pharmaceutical Sciences BrnoBrnoCzech Republic
  5. 5.Department of Biochemistry, Faculty of ScienceMasaryk UniversityBrnoCzech Republic

Personalised recommendations